BRPI0508364A - derivados de 4-benzimidazol-2-ilpiridazin-3-ona - Google Patents

derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Info

Publication number
BRPI0508364A
BRPI0508364A BRPI0508364-8A BRPI0508364A BRPI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A
Authority
BR
Brazil
Prior art keywords
benzimidazol
compounds
derivatives
ylpyridazin
kinase inhibitors
Prior art date
Application number
BRPI0508364-8A
Other languages
English (en)
Inventor
Swen Hoelder
Karl Schoenafinger
David William Will
Hans Matter
Guenther Mueller
Cecile Combeau
Christine Delaisi
Anke Steinmetz
Ingrid Sassoon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0508364A publication Critical patent/BRPI0508364A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

DERIVADOS DE 4-BENZIMIDAZOL-2-ILPIRIDAZIN-3-ONA. A presente invenção refere-se a compostos da fórmula geral (l), onde a definição dos substituintes A, B, D, E, R¬ 1¬ e R¬ 2¬ são detalhadas na descrição, e os seus sais fisioligicamente tolerados, a um processo para a preparação destes compostos e a seu uso como produtos farmacêuticos. Estes compostos são inibidores de quinase, em particular inibidores da quinase CDK2 (quinase 2 dependente de ciclina).
BRPI0508364-8A 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona BRPI0508364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004010207A DE102004010207A1 (de) 2004-03-02 2004-03-02 Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
PCT/EP2005/002569 WO2005085231A1 (en) 2004-03-02 2005-02-18 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives

Publications (1)

Publication Number Publication Date
BRPI0508364A true BRPI0508364A (pt) 2007-07-24

Family

ID=34853913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508364-8A BRPI0508364A (pt) 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Country Status (14)

Country Link
US (2) US7470689B2 (pt)
EP (1) EP1723137A1 (pt)
JP (1) JP4792455B2 (pt)
KR (1) KR20070008582A (pt)
CN (1) CN101061108A (pt)
AR (1) AR047987A1 (pt)
AU (1) AU2005219563A1 (pt)
BR (1) BRPI0508364A (pt)
CA (1) CA2555161A1 (pt)
DE (1) DE102004010207A1 (pt)
IL (1) IL177204A0 (pt)
TW (1) TW200538452A (pt)
UY (1) UY28783A1 (pt)
WO (1) WO2005085231A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
AU2006311914C1 (en) * 2005-11-03 2013-10-24 Chembridge Corporation Heterocyclic compounds as tyrosine kinase modulators
US8247414B2 (en) * 2006-07-25 2012-08-21 Cephalon, Inc. Pyridizinone derivatives and the use thereof as H3 inhibitors
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
ES2766835T3 (es) * 2015-04-16 2020-06-15 Merck Patent Gmbh Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324580A1 (de) 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
DK1005460T3 (da) * 1997-08-22 2006-07-10 Abbott Lab Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
EP1196409B1 (en) * 1999-06-28 2004-02-04 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
MXPA03008690A (es) * 2001-03-28 2003-12-12 Bristol Myers Squibb Co Inhibidores novedosos de tirosina cinasa.
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
PL366889A1 (en) 2001-07-27 2005-02-07 Yamanouchi Pharmaceutical Co, Ltd. Novel crystal of arylethenesulfonamide derivative and process for producing the same
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
EP1441725A1 (en) * 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005519895A (ja) 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
SG159380A1 (en) 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
BR0308109A (pt) 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
HU227255B1 (en) * 2002-04-26 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
CA2488798A1 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
EP1572200B1 (fr) 2002-12-12 2011-08-17 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
IL157751A0 (en) 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
AU2004221966A1 (en) * 2003-03-18 2004-09-30 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US7232939B2 (en) 2004-05-28 2007-06-19 E.I. Du Pont De Nemours And Company Nucleic acid molecules encoding cyclotide polypeptides and methods of use
PT1868999E (pt) 2005-04-06 2009-08-06 Hoffmann La Roche Derivados de piridino-3-carboxamida como agonistas inversos de cb1
US7232901B2 (en) 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
US20070173503A1 (en) 2007-07-26
JP2007531712A (ja) 2007-11-08
KR20070008582A (ko) 2007-01-17
CA2555161A1 (en) 2005-09-15
TW200538452A (en) 2005-12-01
AU2005219563A1 (en) 2005-09-15
US7754713B2 (en) 2010-07-13
IL177204A0 (en) 2006-12-10
WO2005085231A1 (en) 2005-09-15
DE102004010207A1 (de) 2005-09-15
JP4792455B2 (ja) 2011-10-12
US20090042880A1 (en) 2009-02-12
UY28783A1 (es) 2005-09-30
CN101061108A (zh) 2007-10-24
EP1723137A1 (en) 2006-11-22
AR047987A1 (es) 2006-03-15
US7470689B2 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
BRPI0508364A (pt) derivados de 4-benzimidazol-2-ilpiridazin-3-ona
BRPI0510151A (pt) derivados de piridazinona como inibidores de cdk2
BRPI0510410A (pt) compostos orgánicos
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0519674A2 (pt) sulfonil pirrolidinas, mÉtodo para produzir as mesmas e seu uso como drogas
BRPI0510412A (pt) compostos orgánicos
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
BRPI0512797A (pt) derivados de quinazolinona como inibidores de parp
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0515918B8 (pt) sais de composto heterocíclico de ligação à quimiocina, seu processo de preparação e composição farmacêutica que os compreende
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
UY32203A (es) Amino pirimidinas y su uso en terapia
BRPI0014735A (pt) composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação.
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0718813B8 (pt) compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos
BRPI0514091A (pt) 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0817843B8 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BRPI0510409A (pt) heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.